Comparison
503A vs 503B Compounding
Same fields, same evidence rules, both sides. No preselected winner.
This comparison sets out where the two options genuinely differ — mechanism, regulatory status, evidence base, cost path and practical trade-offs — and where the difference is smaller than it is usually presented. It does not recommend one for you.
| Attribute | FDA-approved tirzepatide (Zepbound, Mounjaro) | Compounded tirzepatide |
|---|---|---|
| Regulatory status | Approved finished drug product | Not an FDA-approved product |
| Generic equivalent | No generic tirzepatide exists | Not a generic and not therapeutically equivalent |
| Manufacturing standard | Manufactured under CGMP | Depends on the compounder's registration class |
| Clinical trial evidence | Studied in the registration trials | Trials studied the approved product, not this preparation |
| Labelling | FDA-approved labelling | Supplied by the compounder |
| Presentation | Manufacturer's pens or vials | Varies; multi-dose vials add a measuring step |
| Price read on the seller’s own page | — | — |
A dash means no figure held. How we grade evidence.
| Requirement | 503A compounding pharmacy | 503B outsourcing facility |
|---|---|---|
| Compounds pursuant to | A prescription for an identified individual patient | May compound without patient-specific prescriptions |
| FDA registration | Not registered as an outsourcing facility | Registers with FDA |
| CGMP requirements | Not required to meet CGMP | Must comply with CGMP — though registration alone is not evidence of compliance |
| Primary oversight | State board of pharmacy | FDA, on a risk-based inspection schedule |
| Adverse-event reporting | Not required under 503A | Required to report adverse events to FDA |
| Product approval status | Not an FDA-approved product | Not an FDA-approved product |
| What registration establishes | Not applicable | FDA received the required information, nothing more Verified |
- FDA registered outsourcing facilitiesConfirms a facility is currently registered under 503B, and links the searchable product report database. Registration is not FDA approval and is not evidence of CGMP compliance.
- FDA outsourcing facility registration Q&AThe agency's own explanation of exactly what registration does and does not mean. Worth reading before accepting any provider's characterisation of its pharmacy.
- NABP directory of state boards of pharmacyRoutes you to the board that licenses a pharmacy, and to its licensee and nonresident registers. Check the licence is current, not merely present.
- FSMB directory of state medical boardsRoutes you to the board that licenses a prescriber, and to its public licence lookup. An NPI number is identity in a national registry, not a licence.
Every one of these is the register held by the body that issues the credential. A claim checked against the page that made it has not been checked.
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Show this figure as a table
| Item | Option A | Option B |
|---|---|---|
| Medication | not captured | not captured |
| Required fees | not captured | not captured |
| Twelve-month total | not captured | not captured |
The short version
A 503A pharmacy is a state-licensed pharmacy that compounds for individual patients against a prescription. A 503B outsourcing facility registers with FDA, must follow current good manufacturing practice (CGMP), is inspected by FDA on a risk basis, and can make larger batches without a prescription for each unit. Both routes are set out in the Federal Food, Drug, and Cosmetic Act, in section 503A and section 503B.
For tirzepatide, the practical difference is legal footing. A 503A pharmacy can compound from the drug substance for a named patient, within limits on copying approved products. For 503B, FDA proposed on April 30, 2026 not to place tirzepatide on the bulks list that outsourcing facilities compound from. Comments closed July 30, 2026, and no final decision had been published by November 9, 2026. Neither route produces an FDA-approved product.
Where they actually differ
| 503A pharmacy | 503B outsourcing facility | |
|---|---|---|
| Main overseer | State board of pharmacy | FDA registration and inspection, plus state rules |
| Manufacturing standard | Pharmacy compounding standards, not CGMP | CGMP |
| Prescription | Needed for each identified patient | Not needed for each unit; can supply clinics |
| Reporting to FDA | No routine product reports | Reports what it makes twice a year, plus adverse event reports |
| Source of tirzepatide | Drug substance allowed, but not routinely making copies of an approved product | Depends on the 503B bulks list; FDA proposed excluding tirzepatide |
FDA keeps a list of registered outsourcing facilities. A 503A pharmacy is checked through the board of pharmacy in its home state.
Where they are more similar than claimed
- Neither is FDA-approved. FDA does not review the safety or effectiveness of tirzepatide made by either kind of compounder.
- Both make sterile injections. Both need clean-room technique, and contamination is a risk for both.
- Both get warning letters. FDA enforcement reaches both kinds of compounder. One recent example is warning letter 738238 to Empower Pharmacy, dated September 18, 2026. See our FDA warning letters tracker.
- The vial in your fridge looks the same. It is usually a multi-dose vial with a concentration on the label, and FDA's 28-day discard rule applies after first use.
- The class is not a quality grade. "503B" does not guarantee a given vial, and "503A" does not make one unsafe. Inspection history, licence status and testing disclosures tell you more. Our methodology scores whether a provider names its pharmacy, under pharmacy transparency (15 points).
Cost, all-in
You rarely see the pharmacy's price. You pay the telehealth program, which bundles the clinician, the prescription and the pharmacy fill. So the comparison that matters is between programs, with the pharmacy named.
Across the price index read on October 15, 2026, 33 compounded tirzepatide programs ranged from $69 to $299 a month all-in, with a median of $149. Pharmacy class is not listed on most sellers' price pages, so we cannot say whether it predicts price.
One example: NexLife names three state-licensed 503A pharmacies (Absolute Pharmacy in Lutz, Florida; Premium Compounding in Decatur, Alabama; Boudreaux's New Drug Store in Lake Charles, Louisiana). It charges $129 a month month to month, or $115 a month on a 12-month plan, at every dose with no membership (read November 6, 2026).
Check what the price leaves out: shipping, syringes, membership and dose surcharges. Also check vial size. Medicine left after the 28-day discard date is money lost. See the price index and the pharmacy disclosure register.
Who each option suits
Patients rarely choose the pharmacy class. The program does. These checks help whichever class you end up with:
- Your program uses a 503A pharmacy. Check its licence with the board of pharmacy in its home state. Then check that it is allowed to ship to your state, which often needs a separate non-resident licence.
- Your program uses a 503B facility. Look it up on FDA's outsourcing facility list. Ask how it is supplying tirzepatide while the bulks-list decision is pending.
- Your program will not name its pharmacy. That is a bigger warning sign than either class. Our pharmacy verification tool walks through what to ask.
- You want a product made under CGMP and approved by FDA. Only the brand product is both. See Zepbound vs compounded tirzepatide.
None of this is a recommendation for your treatment.
What the evidence does not settle
- Quality by class. No published study compares potency, sterility failures or patient harm between 503A and 503B tirzepatide.
- Whether inspection prevents harm. FDA inspects 503B facilities, but whether that leads to fewer adverse events with compounded GLP-1s specifically has not been shown.
- The 503B outcome. FDA proposed excluding tirzepatide from the 503B bulks list (91 FR 23431). Comments closed July 30, 2026 (91 FR 38719). A Federal Register search on November 9, 2026 found no final decision.
- How copying limits are enforced. 503A pharmacies may not routinely make copies of an approved product. How that limit is applied to tirzepatide, pharmacy by pharmacy, is not documented in public.
- Independent testing. Most test results come from the pharmacy or a lab it picked. Independent batch testing is rarely published.
Where it holds up
- nothing verified yet
Where it does not
- nothing verified yet
Questions readers actually ask
Which one is better?
Neither, in the abstract. The comparison table shows where each is stronger on a defined field; the right answer depends on your dose, your billing term and what your clinician advises.
Is one of these sponsoring this page?
No. No provider can buy a score, a placement or a review on this site.
Related on this site
- All comparisonsComparisons
- NexLife vs Ro BodyComparisons
- NexLife vs Mochi HealthComparisons
- NexLife vs Henry MedsComparisons
- The 100-point rubricCore & Trust
- Cost calculatorTools
- The underlying price recordsData
- 503B Outsourcing Facility DirectoryPharmacies
- 503A vs 503B: A Patient Verification ChecklistJournal
- 503A Compounding Pharmacy DirectoryPharmacies
Related coverage
Tirzepatide Ranked. “503A vs 503B Compounding.” S.J Partners LLC, 2026-07-26. https://tirzepatideranked.com/compare/503a-vs-503b/
Quote the capture date beside a figure, not the date you read this page. Why.